No Data
ACROBiosystems Launches GMP Brand Resilient Supply at ISSCR to Accelerate Cell and Gene Therapy Development
Baipusi (301080.SZ) plans to distribute 9 yuan per 10 shares, with ex-rights and ex-dividends on July 5.
Baipu Saisi (301080.SZ) announced that the company plans to distribute annual equity dividends in 2023, with a distribution of 1.0 yuan (tax included) for every 10 shares to all shareholders.
Baipsis (301080): Regular business maintains high growth, global layout strategy continues to deepen
Incident: The company released its 2023 annual report and 2024 quarterly report. It achieved operating revenue of 544 million yuan (+14.59%) in 2023, and revenue of 499 million yuan after deducting products related to specific acute respiratory infectious diseases
Baipsis (301080): Overseas routine business maintains high growth and actively lays out clinical business
The company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 544 million yuan (+14.59%, the following are year-on-year values) and net profit to mother was 154 million yuan (-24.61%)
Baipsis (301080): Regular business growth trends are good, R&D reserves are sufficient
Incident: The company released its 2023 annual report, with revenue of 544 million yuan, a year-on-year increase of 14.59%. Net profit to mother was 154 million yuan, a year-on-year decrease of 24.61%, after deducting non-net profit of 140 million yuan, a year-on-year decrease
Baipsis (301080): Revenue is in line with market expectations and deepens global layout strategy
Core Thoughts Bipsis released its annual report for '23 and quarterly reports for '24. The company's business maintained steady growth. Regular business revenue for the full year of '23 reached 498 million yuan, an increase of 29% over the previous year. The global layout has always been an important strategy for the company.
No Data
